Live Chat

Trade Gilead GILD

Sell
 Buy

Gilead live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Info

Spread

0.57

Spread (%)

0.6213 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

117585453056

Shares Outstanding

1246000000

Earnings Date (Next)

2013-01-28

Div Yield

2024-09-27

Ex-Dividend Date

2024-12-13

Forward annual dividend rate

3.08

Forward annual dividend yield

0.0326

EPS

0.09

Learn more about this instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest news

Stay updated with the latest financial news from around the world.

Thursday, 14 November 2024

Dogecoin surges after Elon Musk issues crypto endorsement

Nvidia Blackwell AI Chips

Thursday, 14 November 2024

Week ahead: Tech rally hinges on Nvidia earnings

Dogecoin surges

Wednesday, 13 November 2024

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Wednesday, 13 November 2024

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Wednesday, 13 November 2024

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Tuesday, 12 November 2024

UK stock market news: Helium One share price trading 16.1% higher

Tuesday, 12 November 2024

Leveraged ETF to package Warren Buffett's Berkshire Hathaway B stock

Tuesday, 12 November 2024

Dogecoin surges 20% after Department of Government Efficiency announcement

See all news
Trustpilot
Live Chat